stockrowUltragenyx Pharmaceutical Inc.
RAREUltragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.
- Revenue
- +8.17%
- EPS
- +36.2%
- Free cash flow
- +51.2%
Quarter to September 2026, against a year earlier
Follow RARE
Alert me
Ultragenyx Pharmaceutical Inc. (RARE) Return on invested capital
Ultragenyx Pharmaceutical Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −167.7% (fiscal 2016) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 130.83 |
| FY2021 | −130.8% | (130.83) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 155.57 |
| FY2018 | −155.6% | (17.55) |
| FY2017 | −138.0% | 29.71 |
| FY2016 | −167.7% | (69.44) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PGEN Precigen, Inc. compare | 15.9% |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 0.00% |
| NRIX Nurix Therapeutics, Inc. compare | 0.00% |
| RARE Ultragenyx Pharmaceutical Inc. | 0.00% |
| GENB Generate Biomedicines, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | 0.00% |
| SLS SELLAS Life Sciences Group, Inc. compare | 0.00% |
| STOK Stoke Therapeutics, Inc. compare | −482.0% |
| ADRX ADARx Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)